Therefore, targeting SHP2 in CRC is a potential therapy (Prahallad et al., 2015; Chen et al., 2016; Rehman et al., 2018; García-Aranda and Redondo, 2019). The gene discussed is PTPN11; the disease is colorectal carcinoma.